Apellis Z Score
APLS  Stock  USD 50.36 2.84 5.98% 
Apellis  Z Score 
Apellis Z Score Analysis
Apellis Pharmaceuticals' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2021  2022 (projected)  
PPandE Turnover  10.26  10.52 
Long Term Debt to Equity  0.95  1.11 
Z Score  =  Sum Of   5 Factors 
Current Apellis Pharmaceuticals Z Score  6.4 
Most of Apellis Pharmaceuticals' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apellis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Apellis Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Apellis Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Apellis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apellis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apellis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
In accordance with the company's disclosures, Apellis Pharmaceuticals has a Z Score of 6.4. This is 194.81% lower than that of the Biotechnology sector and 291.62% lower than that of the Health Care industry. The z score for all United States stocks is 173.39% higher than that of the company.
Apellis Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.Apellis Pharmaceuticals is currently under evaluation in z score category among related companies.
Apellis Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Apellis Pharmaceuticals from analyzing Apellis Pharmaceuticals' financial statements. These drivers represent accounts that assess Apellis Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Apellis Pharmaceuticals' important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (1.31 M)  (1.47 M)  (1.3 M)  (919.6 K)  (1.57 M)  (1.69 M)  
Average Assets  104.78 M  218.18 M  372.66 M  821.99 M  729.37 M  603.86 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (50.88 M)  (127.3 M)  (304.29 M)  (316.62 M)  (731.8 M)  (751.06 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (50.63 M)  (124.99 M)  (298.83 M)  (312.23 M)  (731.27 M)  (750.51 M)  
Earnings before Tax  (51.01 M)  (127.5 M)  (304.71 M)  (343.03 M)  (746 M)  (765.63 M)  
Average Equity  86.37 M  178.88 M  139.41 M  200.36 M  12.88 M  13.21 M  
Free Cash Flow  (46.6 M)  (131.24 M)  (212.83 M)  (165.91 M)  (564.23 M)  (579.08 M)  
Invested Capital  26.32 M  37.29 M  128.54 M  642.93 M  318.38 M  262.8 M  
Invested Capital Average  12.63 M  31.44 M  74.77 M  631.45 M  556.3 M  600.22 M  
Tangible Asset Value  182.13 M  203.53 M  389.25 M  960.57 M  881.76 M  951.38 M  
Working Capital  175.46 M  185.41 M  307.34 M  788.87 M  692.2 M  546.92 M 
Apellis Fundamentals
Return On Equity  (5.07) %  
Return On Asset  (0.46) %  
Operating Margin  (4.60) %  
Current Valuation  5 B  
Shares Outstanding  110.58 M  
Shares Owned by Insiders  15.09 %  
Shares Owned by Institutions  89.65 %  
Number of Shares Shorted  10.39 M  
Price to Earning  (6.94) X  
Price to Book  18.21 X  
Price to Sales  49.26 X  
Revenue  66.56 M  
Gross Profit  (253.92 M)  
EBITDA  (731.27 M)  
Net Income  (746.35 M)  
Cash and Equivalents  852.8 M  
Cash per Share  7.76 X  
Total Debt  189.02 M  
Debt to Equity  0.63 %  
Current Ratio  7.57 X  
Book Value Per Share  2.78 X  
Cash Flow from Operations  (563.13 M)  
Short Ratio  6.43 X  
Earnings Per Share  (7.87) X  
Price to Earnings To Growth  (0.30) X  
Target Price  76.38  
Number of Employees  476  
Beta  1.17  
Market Capitalization  5.57 B  
Total Asset  881.76 M  
Retained Earnings  (596.77 M)  
Working Capital  110.69 M  
Current Asset  115.82 M  
Current Liabilities  5.13 M  
Z Score  6.4  
Net Asset  881.76 M 
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Apellis Pharmaceuticals, Inc., a commercialstage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people.
Apellis Pharmaceuticals Investors Sentiment
The influence of Apellis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Apellis. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Apellis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Apellis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Apellis Pharmaceuticals' short interest history, or implied volatility extrapolated from Apellis Pharmaceuticals options trading.
Pair Trading with Apellis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Apellis Pharmaceuticals
+  0.78  EW  Edwards Lifesciences Corp  Selloff Trend  PairCorr 
Moving against Apellis Pharmaceuticals
  0.74  JPM  JPMorgan Chase  Fiscal Year End 13th of January 2023  PairCorr  
  0.6  PFE  Pfizer Inc  Aggressive Push  PairCorr  
  0.51  KAKZF  Kaspi Bank Joint  Trending  PairCorr 
The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Please continue to Apellis Pharmaceuticals Piotroski F Score and Apellis Pharmaceuticals Valuation analysis. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for analysis
When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals  Go  
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency  Go  
Piotroski F ScoreGet Piotroski F Score based on binary analysis strategy of nine different fundamentals  Go  
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and roboadvisors.  Go  
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data  Go 
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 5.6 B  Quarterly Revenue Growth YOY 2.904  Return On Assets (0.46)  Return On Equity (5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.